Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate

Mult Scler. 2020 Sep;26(10):1227-1236. doi: 10.1177/1352458519854162. Epub 2019 May 30.

Abstract

Background: Brain magnetic resonance imaging (MRI) is the most effective surveillance tool for the detection of asymptomatic progressive multifocal leukoencephalopathy (PML). However, the optimal frequency for routine MRI surveillance is under-investigated.

Objective: To understand whether, upon their first MRI appearance, PML lesions present a difference in volume when comparing patients who frequently underwent MRI surveillance (3/4 months) with those who were assessed at longer intervals (6/12 months) and to understand the impact of the volume of lesions on clinical outcome.

Methods: The data of patients included in the Italian PML cohort were retrospectively analysed. Patients who had all the pre-diagnostic MRI scans available (n = 37) were included. The volume of PML lesion was calculated by manually outlining the PML lesion.

Results: Compared with patients who underwent MRI examination at least every 4 months, patients who were assessed less frequently had a lesion of significantly higher volume (median: 2567 (883-3583) vs. 664 mm3 (392-963) p = 0.006) and suffered a higher rate of disability (median: 2.25 expanded disability status scale points (-2.5 to 8) vs. 0.5 (-1 to 2.5) p = 0.004).

Conclusion: The positive clinical outcome of patients undergoing frequent MRI surveillance and the small volume of the PML lesion upon first appearance justify a frequent surveillance using MRI in patients at high risk of PML.

Keywords: Natalizumab; high frequency MRI; lesion volume; progressive multifocal leukoencephalopathy.

MeSH terms

  • Brain / diagnostic imaging
  • Humans
  • Leukoencephalopathy, Progressive Multifocal* / diagnostic imaging
  • Magnetic Resonance Imaging
  • Natalizumab / adverse effects
  • Retrospective Studies

Substances

  • Natalizumab